Chemours stock falls after Truist maintains buy rating despite guidance cut

Chemours (CC) shares declined after the company lowered its Q2 adjusted EBITDA guidance to $215-$225 million, below the $236 million consensus, citing operational disruptions at its U.S. titanium dioxide facilities due to a rail line service interruption. Despite this, Truist Securities maintained a buy rating with a $20 price target, noting strength in the Thermal & Specialized Solutions (TSS) segment driven by Opteon demand and improved profitability in Advanced Performance Materials (APM). While the titanium dioxide issues appear temporary, Chemours anticipates strong sequential net sales growth of approximately 25% within the TSS segment, driven by demand for Opteon refrigerants.

Analysis

Chemours (NYSE:CC) has revised its second-quarter adjusted EBITDA guidance downwards to $215 million - $225 million, falling short of Wall Street's $236 million consensus, primarily due to operational disruptions, specifically a rail line service interruption impacting feedstock procurement at its U.S. Titanium Technologies facilities. This news contributed to a significant stock decline, with shares falling on Tuesday and experiencing a 9.5% drop over the past week and a 36.6% decrease over the last six months, trading at $11.37. Despite the guidance cut and eight analysts revising earnings estimates downward, Truist Securities maintained a buy rating and a $20.00 price target. Truist highlighted that Chemours increased EBITDA guidance for its other two segments, particularly noting strong performance in the Thermal & Specialized Solutions (TSS) division, which anticipates approximately 25% sequential net sales growth driven by higher-than-anticipated demand for Opteon refrigerants amid U.S. regulations favoring low global warming potential options. Chemours also kept its Titanium Technologies sales guidance unchanged, which Truist views as a more reliable indicator of market conditions than the segment's adjusted EBITDA, and pointed to improved profitability in the Advanced Performance Materials (APM) segment. The company now projects consolidated net sales to rise by mid-teens sequentially for the second quarter, reaching the high end of its original forecast range, and anticipates positive free cash flow. However, the Titanium Technologies segment is expected to see a 15% sequential decline in adjusted EBITDA. InvestingPro data suggests Chemours is currently undervalued, albeit while managing a significant debt burden and exhibiting volatile stock performance. Strategic initiatives include new executive appointments (Matthew Conti as CHRO, Nathan Blom as VP for liquid cooling) and a partnership with DataVolt to enhance data center efficiency using liquid cooling technologies, signaling a focus on growth areas.

Key Decisions for Investors

• Investors should closely monitor the resolution of operational issues within the Titanium Technologies segment and their impact on future EBITDA contributions, as these are presented as temporary.
• Consider the offsetting strength in the Thermal & Specialized Solutions and Advanced Performance Materials segments, particularly the growth drivers from Opteon demand and new applications like liquid cooling, against the backdrop of the company's significant debt burden.
• Evaluate whether the current depressed stock price, cited as undervalued by InvestingPro, adequately reflects the risks associated with the Titanium Technologies segment's disruption and overall stock volatility, or if it presents a potential opportunity given the positive outlook for other business lines and strategic initiatives.